Literature DB >> 28044435

Expanding the cerebrospinal fluid endopeptidome.

Karl T Hansson1, Tobias Skillbäck1,2, Elin Pernevik1, Silke Kern1,2, Erik Portelius1,2, Kina Höglund1,2, Gunnar Brinkmalm1, Jessica Holmén-Larsson1, Kaj Blennow1,2, Henrik Zetterberg1,2,3, Johan Gobom1,2.   

Abstract

Biomarkers of neurodegenerative disorders are needed to assist in diagnosis, to monitor disease progression and therapeutic interventions, and to provide insight into disease mechanisms. One route to identify such biomarkers is by proteomic and peptidomic analysis of cerebrospinal fluid (CSF). In the current study, we performed an in-depth analysis of the human CSF endopeptidome to establish an inventory that may serve as a basis for future targeted biomarker studies. High-pH RP HPLC was employed for off-line sample prefractionation followed by low-pH nano-LC-MS analysis. Different software programs and scoring algorithms for peptide identification were employed and compared. A total of 18 031 endogenous peptides were identified at a FDR of 1%, increasing the number of known endogenous CSF peptides 10-fold compared to previous studies. The peptides were derived from 2 053 proteins of which more than 60 have been linked to neurodegeneration. Notably, among the findings were six peptides derived from microtubule-associated protein tau, three of which span the diagnostically interesting threonine-181 (Tau-F isoform). Also, 213 peptides from amyloid precursor protein were identified, 58 of which were partially or completely within the sequence of amyloid β 1-40/42, as well as 109 peptides from apolipoprotein E, spanning sequences that discriminate between the E2/E3/E4 isoforms of the protein.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Neurodegeneration; Peptidomics

Mesh:

Substances:

Year:  2017        PMID: 28044435     DOI: 10.1002/pmic.201600384

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  13 in total

1.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

2.  Characterization of Cerebrospinal Fluid BACE1 Species.

Authors:  Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2019-07-09       Impact factor: 5.590

3.  Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid.

Authors:  Karl T Hansson; Tobias Skillbäck; Elin Pernevik; Jessica Holmén-Larsson; Gunnar Brinkmalm; Kaj Blennow; Henrik Zetterberg; Johan Gobom
Journal:  J Vis Exp       Date:  2017-12-04       Impact factor: 1.355

Review 4.  Peptidomic Approaches and Observations in Neurodegenerative Diseases.

Authors:  Besnik Muqaku; Patrick Oeckl
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

5.  Combining mass spectrometry and machine learning to discover bioactive peptides.

Authors:  Mads Grønborg; Ulrik de Lichtenberg; Christian T Madsen; Jan C Refsgaard; Felix G Teufel; Sonny K Kjærulff; Zhe Wang; Guangjun Meng; Carsten Jessen; Petteri Heljo; Qunfeng Jiang; Xin Zhao; Bo Wu; Xueping Zhou; Yang Tang; Jacob F Jeppesen; Christian D Kelstrup; Stephen T Buckley; Søren Tullin; Jan Nygaard-Jensen; Xiaoli Chen; Fang Zhang; Jesper V Olsen; Dan Han
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

6.  Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.

Authors:  Karl Hansson; Rahil Dahlén; Oskar Hansson; Elin Pernevik; Ross Paterson; Jonathan M Schott; Nadia Magdalinou; Henrik Zetterberg; Kaj Blennow; Johan Gobom
Journal:  Clin Mass Spectrom       Date:  2019-07-15

Review 7.  Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2017-09-04       Impact factor: 6.543

8.  Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.

Authors:  Justin McKetney; Daniel J Panyard; Sterling C Johnson; Cynthia M Carlsson; Corinne D Engelman; Joshua J Coon
Journal:  Proteomics Clin Appl       Date:  2021-04-26       Impact factor: 3.494

Review 9.  Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.

Authors:  Magdalena Korecka; Leslie M Shaw
Journal:  J Neurochem       Date:  2021-08-25       Impact factor: 5.546

10.  Progress in brain barriers and brain fluid research in 2017.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.